Clinical outcomes of the EyeWatch system: three-year results.
Liegl Constance, Hundertmark Sarah, Holz Frank G, Mercieca Karl
AI Summary
The EyeWatch system effectively lowered IOP in refractory glaucoma over three years, reducing medication needs. Most adjustments were early, but MRI caused transient IOP spikes.
Abstract
What is known: The EyeWatch™ System (EWS) is an adjustable glaucoma drainage device that allows non-invasive postoperative intraocular pressure (IOP) control. Early studies have shown promising short- and mid-term results with EWS in managing refractory glaucoma.
What is new: This study presents the first three-year clinical outcomes of EWS implantation, showing a sustained IOP reduction from a preoperative mean of 34.6 mmHg to 13.6 mmHg, with all patients achieving IOP levels below 21 mmHg and a significant decrease in medication burden. Most device adjustments occurred within the first postoperative year, after which IOP remained stable without further intervention. A transient IOP elevation following MRI underscores the importance of monitoring EWS patients in the context of magnetic exposure.
Shields Classification
Key Concepts6
Three-year clinical outcomes of EyeWatch System (EWS) implantation showed a sustained intraocular pressure (IOP) reduction from a preoperative mean of 34.6 mmHg to 13.6 mmHg, with all patients achieving IOP levels below 21 mmHg.
EyeWatch System (EWS) implantation resulted in a significant decrease in medication burden over three years.
Most EyeWatch System (EWS) device adjustments occurred within the first postoperative year, after which intraocular pressure (IOP) remained stable without further intervention.
A transient intraocular pressure (IOP) elevation following MRI underscores the importance of monitoring EyeWatch System (EWS) patients in the context of magnetic exposure.
The EyeWatch System (EWS) is an adjustable glaucoma drainage device that allows non-invasive postoperative intraocular pressure (IOP) control.
Early studies have shown promising short- and mid-term results with the EyeWatch System (EWS) in managing refractory glaucoma.
Related Articles5
The Paul Glaucoma Implant: a systematic review of safety, efficacy, and emerging applications.
Systematic ReviewLong-term comparative outcomes of Hydrus versus iStent inject microinvasive glaucoma surgery implants combined with cataract surgery.
Observational StudySpecial Commentary: Reporting Clinical Endpoints in Studies of Minimally Invasive Glaucoma Surgery.
ReviewTwo-year outcomes of Xen 45 gel stent implantation in patients with open-angle glaucoma: real-world data from the Fight Glaucoma Blindness registry.
Observational StudyThe use of intraluminal PRESERFLO stenting in avoiding early postoperative hypotony.
Observational StudyIs this article assigned to the wrong chapter(s)? Let us know.